Current immunotherapeutic treatment options for ovarian cancer include but are not limited to therapy with antibodies (Abs) for example against CA125 and idiotypic antibodies, cytokines (such as IFNγ, IL-2), active immunization with gene transduced whole tumor cells, peptide-based vaccines, dendritic cell vaccines and heat shock protein (HSP) vaccines. The gene discussed is HSP90B2P; the disease is ovarian carcinoma.